Third-Generation PCSK9 Inhibitor Cuts Cholesterol With Single, Small, Monthly Shot

(MedPage Today) -- ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by 56% more than placebo from...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news